Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results Life Science Investing
Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development Life Science Investing
Standard BioTools Announces Sale of Mass Cytometry Business and Illumina's Buyout of Contingent Payments to Advance Merger with Treeline Biosciences Biotech Investing
Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026 Life Science Investing
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy Life Science Investing
Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates Life Science Investing
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus Life Science Investing
CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® in Children with Hereditary Angioedema Life Science Investing
